The Latest News

November 1, 2021

PRISM BioLab raised 100 million yen in Series C funding from Eisai

PRISM BioLab, the Japan based biotechnology company with proprietary small molecule drug discovery technology ”PepMetics™”, today announced that it has...
Read More

About
PRISM BIOLAB

MISSION:
PRISM BioLab is committed to maximizing the potential of its PepMetics™ Technology, transforming the “undruggable” to “druggable” with the aim of finding cures for the incurable.

PRISM BioLab is a biotechnology company with PepMetics Technology, a proprietary drug discovery platform. PepMetics Molecules are designed to mimic α-helix or β-turn peptides using unique, stable scaffolds.

PepMetics
Technology

We synthesize like a small molecule, but our PepMetic Molecules act like peptides.

Peptide
MIMETICS

“PepMetics”TM
LIBRARY

PRISM’s PepMetics Real Library includes 20,000+ compounds covering various amino acid sequences for screening. The PepMetics Library is used to generate hits for difficult targets.